Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients

Elena Ricart, Remo Panaccione, Edward V. Loftus, William J. Tremaine, William J. Sandborn

Research output: Contribution to journalArticle

261 Scopus citations

Abstract

OBJECTIVE: The aim of this study was to report the clinical outcome and adverse events in the first 100 patients with refractory inflammatory and/or fistulizing Crohn's disease treated with infliximab at the Mayo Clinic. METHODS: Patient data was abstracted from medical records. Clinical response was classified as complete response, partial response, and nonresponse. RESULTS: Indications for infliximab therapy were: inflammatory disease (61 patients), fistulizing disease (26 patients), or both (13 patients). Patients received one to seven infusions of infliximab (5 mg/kg) for a total of 242 infusions. In all, 50 patients had complete response, 22 had partial response, and 28 had nonresponse. Median time to response was 7 days (range 1-21 days). Median duration of response was 10.3 weeks (range 3-25 wk). A total of 95 patients received concomitant treatment with immune modifiers. Steroid withdrawal was possible in 29/40 patients (73%). Median time of follow-up was 34 wk (range 14-48 wk). Clinically significant adverse events after infliximab included: abscess formation in two patients (perianal, peristomal), pneumonia in two patients, varicella zoster in three patients, candida esophagitis in one patient, and infusion-related reactions in 19 patients. A total of 23 patients were continued on infliximab as maintenance treatment. CONCLUSIONS: This study provides additional evidence that infliximab is safe and beneficial in clinical practice for refractory Crohn's disease.

Original languageEnglish (US)
Pages (from-to)722-729
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume96
Issue number3
DOIs
StatePublished - Apr 5 2001

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients'. Together they form a unique fingerprint.

  • Cite this